CARLSMED, INC. (CARL) — Quarterly Report

Key Insights

• The filing date of May 5, 2026 for Q1 2026 (ending March 31, 2026) appears delayed, suggesting potential operational or reporting challenges that warrant investigation into internal controls and financial close processes.
• Multiple convertible preferred stock series (A, B, C) and warrant instruments indicate a complex capital structure with significant dilution potential for common shareholders, requiring careful monitoring of conversion triggers and exercise terms.
• The presence of a Fifth Amendment to a loan agreement dated October 29, 2025 suggests the company has required multiple restructuring negotiations with lenders, indicating potential liquidity or covenant compliance concerns that investors should examine in detail.
• Customer concentration risk is explicitly tracked in the filing, suggesting reliance on major customers that could materially impact revenue stability; this warrants review of customer contracts and retention metrics.